Developer docs
API playgroundTry for free, no card

Search company profiles

Oscotec

Full company profile

uuid003ejh1

Namestring
Oscotec
Legal namestring
Oscotec Inc.
Websiteurl
oscotec.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Oscotec Inc. is a Seongnam, South Korea-based clinical-stage drug discovery company that discovers and develops small-molecule and antibody therapeutics in immunology and oncology. Founded in 1998 and KOSDAQ-listed (kosdaq:039200) since 2007, the company operates its central R&D center from Korea Bio-Park with a Boston-based R&D subsidiary (Genosco Inc., separated in 2016) and maintains a lean organization of 11–50 employees. Its pipeline comprises six named drug candidates built around novel mechanisms of action: Lazertinib (third-generation EGFR inhibitor), Cevidoplenib (SYK inhibitor), Denfivontinib (FLT3/AXL dual inhibitor), Adel-Y01 (anti-acetylated-tau monoclonal antibody), OCT-598 (EP2/4 dual antagonist), and OCT-648 (NUAK1 inhibitor). The discovery engine relies on hypothesis-driven medicinal chemistry and rigorous target-disease validation, with scientific leadership drawn from Yale, Caltech, the University of Pennsylvania, Novartis Pharma, and Dong-A ST.

The company's business model is asset-centric out-licensing rather than direct commercialization. Oscotec advances candidates to clinical proof-of-concept or key regulatory milestones, then transfers global development and commercialization rights to pharmaceutical partners in exchange for upfront payments, development and regulatory milestones, and tiered royalties. Disclosed deal economics include the 2018 Yuhan-to-Janssen transfer for Lazertinib ($1.255 billion total), the December 2025 Sanofi license for Adel-Y01 ($80 million upfront plus up to $1.04 billion total deal value), and the June 2026 Agios license for Cevidoplenib ($25 million upfront plus up to $140 million in milestones). Recurring royalty revenue flows from Lazertinib, where Oscotec retains 10–15% of net sales through a 6:2:2 distribution arrangement with Yuhan and Genosco; Q1 2025 royalty receipts were KRW 1.289 billion.

The customer base consists entirely of global pharmaceutical partners: Sanofi, Janssen/Johnson & Johnson, Yuhan Corporation, Agios Pharmaceuticals, Yatiri Bio, and ADEL Inc. The company supplements in-house discovery with co-development agreements, including Kanaph Therapeutics (EP2/4 program), Beactica (LSD1), Biorevert (BRVT121/221), and ADEL (Adel-Y01), and pursues new partnerships through industry events such as BIO USA. The lean headcount and absence of commercial infrastructure are consistent with a discovery-engine operating model that monetizes innovation through licensing rather than through integrated pharmaceutical sales.

Short descriptiontext

Oscotec is a Seongnam, South Korea-based clinical-stage biotech that discovers small-molecule and antibody therapeutics in oncology and immunology, advancing six candidates through out-licensing partnerships with global pharmaceutical companies for milestone and royalty revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, small molecule therapeutics, clinical stage biotech, targeted oncology therapies, immunology drug development
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage drug discovery and development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Royalties
TypeLicensing Royalties
Description

Oscotec receives royalty revenues based on sales performance of licensed drugs. For Lazertinib, royalties are distributed among Yuhan, Oscotec, and Genosco in a 6:2:2 ratio, with Oscotec receiving 10-15% of net sales globally.

oscotec.com
2Milestone Payments
TypeLicensing Royalties
Description

Upfront and development/regulatory milestone payments from licensing agreements. Cevidoplenib deal with Agios: $25M upfront plus up to $140M in milestones. Adel-Y01 deal with Sanofi: $80M upfront with potential total value up to $1.04B.

endpoints.news
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1SKI-O-703
Description

SYK inhibitor program by Oscotec

oscotec.com
+3 more records
Core offering1 text field

Oscotec is a clinical-stage drug discovery company that discovers and develops small-molecule targeted therapeutics and biologics with novel mechanisms of action in oncology and immunology. The company monetizes its pipeline through out-licensing deals with global pharmaceutical partners, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Lazertinib combination therapy extended overall survival by more than 12 months compared to Tagrisso in Phase 3 MARIPOSA trial
+3 more records
Product overview1 text field

Oscotec is a clinical-stage South Korean drug discovery and development company focused on targeted therapeutics in immunology and oncology. The company's pipeline consists of six named drug candidates: Lazertinib (EGFR inhibitor, partnered with Janssen), Cevidoplenib (SYK inhibitor, licensed to Agios), Denfivontinib (FLT3/AXL inhibitor), Adel-Y01 (anti-Tau antibody, licensed to Sanofi), OCT-598 (EP2/4 antagonist), and OCT-648 (NUAK1 inhibitor). Oscotec operates a discovery engine model, identifying small molecules with novel mechanisms of action and validating drug-target-disease hypotheses through rigorous science to clinical proof-of-concept.

Product and service6 records
1Lazertinib (YH25448)
CategoryDrug Candidate - Oncology
Description

Third-generation EGFR inhibitor for EGFR-mutant non-small cell lung cancer (NSCLC). Licensed to Yuhan Corporation and sublicensed to Janssen Biotech for USD 1.255 billion in 2018. Demonstrated extended overall survival by more than 12 months compared to Tagrisso in Phase 3 MARIPOSA trial when combined with Rybrevant.

2Cevidoplenib (SKI-O-703)
CategoryDrug Candidate - Immunology
Description

Selective SYK inhibitor for rheumatoid arthritis (RA) and immune thrombocytopenia (ITP). Demonstrated excellent safety profile in Phase 2 trials with rapid onset of clinical response within two weeks. In high-dose treatment group, 73% of patients achieved greater than or equal to 2-fold increase in platelet counts versus 25% on placebo, and 41% of patients reached platelet counts greater than or equal to 50,000/microL.

3Denfivontinib (SKI-G-801)
CategoryDrug Candidate - Oncology
Description

FLT3/AXL dual inhibitor for acute myeloid leukemia (AML) and solid tumors. Addresses FLT3 mutations found in approximately 30-35% of AML patients and AXL overexpression associated with therapy resistance in solid tumors. Demonstrated anti-leukemic activity in patient-derived samples and immune-dependent anti-tumor effects.

4Adel-Y01
CategoryDrug Candidate - Neurology
Description

Anti-Tau monoclonal antibody targeting acetylated K280 (acK280) epitope for Alzheimer's disease. Selectively targets disease-specific pathological tau rather than normal tau. Co-developed with ADEL Inc. Holds first-in-class potential among anti-Tau antibodies.

5OCT-598
CategoryDrug Candidate - Oncology
Description

EP2/4 dual antagonist for solid tumors. Targets prostaglandin E2 signaling to prevent tumor recurrence by inhibiting cancer cell regeneration and therapy resistance.

6OCT-648
CategoryDrug Candidate - Renal/Fibrosis
Description

NUAK1 inhibitor targeting renal fibrosis and chronic kidney disease (CKD). Novel mechanism modulating YAP/TAZ signaling pathway with demonstrated anti-fibrotic efficacy in preclinical models.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-06-01
Description

Agios licensed exclusive global rights to Oscotec's cevidoplenib (next-generation SYK inhibitor) for immune thrombocytopenia. Oscotec received $25 million upfront with potential additional payments of up to $140 million in development and regulatory milestones plus tiered royalties on future net sales. Agios plans Phase 3 trials for ITP in H1 2028, targeting peak U.S. sales potential of up to $1 billion.

Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Yatiri Bio entered exclusive option to in-license denfivontinib (FLT3/AXL dual inhibitor) for acute myeloid leukemia (AML). This provides Yatiri access to Oscotec's oncology asset.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-12-15
Description

Sanofi licensed global rights to ADEL-Y01 (anti-Tau antibody for Alzheimer's disease) co-developed with Oscotec since 2020. Deal valued at up to $1.04 billion including $80M upfront and additional milestone payments plus royalties. The antibody targets acetylated K280 (acK280) epitope and holds first-in-class potential.

4Biorevert Inc.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Co-development agreement for BRVT121 and BRVT221. Biorevert partnership expands Oscotec's pipeline in additional therapeutic areas.

oscotec.com
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Co-development agreement for EP2/4 program (OCT-598). Kanaph brings genome-driven drug target discovery capabilities; partnership worth approximately KRW 774.8 billion in cumulative deal value.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Joint R&D agreement for LSD1 program. Beactica contributes specialized drug discovery capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-10-01
Description

Co-development agreement for ADEL-Y01 (anti-Tau antibody for Alzheimer's disease). Oscotec contributed discovery expertise; ADEL advanced the program through Phase 1 before out-licensing to Sanofi in December 2025.

8Ectodor Therapeutics Inc.
Strategic tierInternalTypeOthersAnnounced on2020-10-01
Description

Oscotec established Ectodor Therapeutics Inc. as a subsidiary in October 2020 to support broader corporate strategy.

oscotec.com
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2018-11-01
Description

Janssen licensed Lazertinib from Yuhan (which licensed from Oscotec subsidiary Genosco). Deal valued at $1.255 billion. Lazertinib is a 3rd generation EGFR inhibitor. FDA approved combination with Rybrevant in August 2024.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2015-07-01
Description

Oscotec licensed EGFR-targeted anti-cancer drug candidate (Lazertinib) to Yuhan in 2015. Yuhan further licensed to Janssen in 2018 for $1.255 billion. Yuhan distributes royalties to Oscotec (10-15% of net sales, distributed 6:2:2 with Genosco).

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oscotec

Clinical-stage drug discovery and developmentoscotec.com

Oscotec is a Seongnam, South Korea-based clinical-stage biotech that discovers small-molecule and antibody therapeutics in oncology and immunology, advancing six candidates through out-licensing partnerships with global pharmaceutical companies for milestone and royalty revenue.

What Oscotec does

Oscotec Inc. is a Seongnam, South Korea-based clinical-stage drug discovery company that discovers and develops small-molecule and antibody therapeutics in immunology and oncology. Founded in 1998 and KOSDAQ-listed (kosdaq:039200) since 2007, the company operates its central R&D center from Korea Bio-Park with a Boston-based R&D subsidiary (Genosco Inc., separated in 2016) and maintains a lean organization of 11–50 employees. Its pipeline comprises six named drug candidates built around novel mechanisms of action: Lazertinib (third-generation EGFR inhibitor), Cevidoplenib (SYK inhibitor), Denfivontinib (FLT3/AXL dual inhibitor), Adel-Y01 (anti-acetylated-tau monoclonal antibody), OCT-598 (EP2/4 dual antagonist), and OCT-648 (NUAK1 inhibitor). The discovery engine relies on hypothesis-driven medicinal chemistry and rigorous target-disease validation, with scientific leadership drawn from Yale, Caltech, the University of Pennsylvania, Novartis Pharma, and Dong-A ST.

The company's business model is asset-centric out-licensing rather than direct commercialization. Oscotec advances candidates to clinical proof-of-concept or key regulatory milestones, then transfers global development and commercialization rights to pharmaceutical partners in exchange for upfront payments, development and regulatory milestones, and tiered royalties. Disclosed deal economics include the 2018 Yuhan-to-Janssen transfer for Lazertinib ($1.255 billion total), the December 2025 Sanofi license for Adel-Y01 ($80 million upfront plus up to $1.04 billion total deal value), and the June 2026 Agios license for Cevidoplenib ($25 million upfront plus up to $140 million in milestones). Recurring royalty revenue flows from Lazertinib, where Oscotec retains 10–15% of net sales through a 6:2:2 distribution arrangement with Yuhan and Genosco; Q1 2025 royalty receipts were KRW 1.289 billion.

The customer base consists entirely of global pharmaceutical partners: Sanofi, Janssen/Johnson & Johnson, Yuhan Corporation, Agios Pharmaceuticals, Yatiri Bio, and ADEL Inc. The company supplements in-house discovery with co-development agreements, including Kanaph Therapeutics (EP2/4 program), Beactica (LSD1), Biorevert (BRVT121/221), and ADEL (Adel-Y01), and pursues new partnerships through industry events such as BIO USA. The lean headcount and absence of commercial infrastructure are consistent with a discovery-engine operating model that monetizes innovation through licensing rather than through integrated pharmaceutical sales.

Oscotec firmographics

Firmographics
Name
Oscotec
Legal name
Oscotec Inc.
Website
https://oscotec.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Oscotec is a Seongnam, South Korea-based clinical-stage biotech that discovers small-molecule and antibody therapeutics in oncology and immunology, advancing six candidates through out-licensing partnerships with global pharmaceutical companies for milestone and royalty revenue.
Ownership category
akta.pro rank

Oscotec industry classification

Industry
Product category
Clinical-stage drug discovery and development
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Drug discovery services
  • Small molecule therapeutics
  • Clinical stage biotech
  • Targeted oncology therapies
  • Immunology drug development

Where Oscotec is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Oscotec business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Licensing Royalties: Oscotec receives royalty revenues based on sales performance of licensed drugs. For Lazertinib, royalties are distributed among Yuhan, Oscotec, and Genosco in a 6:2:2 ratio, with Oscotec receiving 10-15% of net sales globally.
  2. Milestone Payments: Upfront and development/regulatory milestone payments from licensing agreements. Cevidoplenib deal with Agios: $25M upfront plus up to $140M in milestones. Adel-Y01 deal with Sanofi: $80M upfront with potential total value up to $1.04B.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Oscotec product offering

Product offering

Core offering

Oscotec is a clinical-stage drug discovery company that discovers and develops small-molecule targeted therapeutics and biologics with novel mechanisms of action in oncology and immunology. The company monetizes its pipeline through out-licensing deals with global pharmaceutical partners, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Product overview

Oscotec is a clinical-stage South Korean drug discovery and development company focused on targeted therapeutics in immunology and oncology. The company's pipeline consists of six named drug candidates: Lazertinib (EGFR inhibitor, partnered with Janssen), Cevidoplenib (SYK inhibitor, licensed to Agios), Denfivontinib (FLT3/AXL inhibitor), Adel-Y01 (anti-Tau antibody, licensed to Sanofi), OCT-598 (EP2/4 antagonist), and OCT-648 (NUAK1 inhibitor). Oscotec operates a discovery engine model, identifying small molecules with novel mechanisms of action and validating drug-target-disease hypotheses through rigorous science to clinical proof-of-concept.

Differentiator

Problem solved

Functional benefit

Brands

  • SKI-O-703: SYK inhibitor program by Oscotec
  • Denfivontinib
  • SKI-G-801
  • SKI-G-749

Products and services

  • Lazertinib (YH25448) Third-generation EGFR inhibitor for EGFR-mutant non-small cell lung cancer (NSCLC). Licensed to Yuhan Corporation and sublicensed to Janssen Biotech for USD 1.255 billion in 2018. Demonstrated extended overall survival by more than 12 months compared to Tagrisso in Phase 3 MARIPOSA trial when combined with Rybrevant.
  • Cevidoplenib (SKI-O-703) Selective SYK inhibitor for rheumatoid arthritis (RA) and immune thrombocytopenia (ITP). Demonstrated excellent safety profile in Phase 2 trials with rapid onset of clinical response within two weeks. In high-dose treatment group, 73% of patients achieved greater than or equal to 2-fold increase in platelet counts versus 25% on placebo, and 41% of patients reached platelet counts greater than or equal to 50,000/microL.
  • Denfivontinib (SKI-G-801) FLT3/AXL dual inhibitor for acute myeloid leukemia (AML) and solid tumors. Addresses FLT3 mutations found in approximately 30-35% of AML patients and AXL overexpression associated with therapy resistance in solid tumors. Demonstrated anti-leukemic activity in patient-derived samples and immune-dependent anti-tumor effects.
  • Adel-Y01 Anti-Tau monoclonal antibody targeting acetylated K280 (acK280) epitope for Alzheimer's disease. Selectively targets disease-specific pathological tau rather than normal tau. Co-developed with ADEL Inc. Holds first-in-class potential among anti-Tau antibodies.
  • OCT-598 EP2/4 dual antagonist for solid tumors. Targets prostaglandin E2 signaling to prevent tumor recurrence by inhibiting cancer cell regeneration and therapy resistance.
  • OCT-648 NUAK1 inhibitor targeting renal fibrosis and chronic kidney disease (CKD). Novel mechanism modulating YAP/TAZ signaling pathway with demonstrated anti-fibrotic efficacy in preclinical models.

Quantifiable outcome

  • Lazertinib combination therapy extended overall survival by more than 12 months compared to Tagrisso in Phase 3 MARIPOSA trial
  • +3 more outcomes

Companies that use Oscotec

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Oscotec technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Oscotec partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major, moderate, minor and internal.

  • Agios PharmaceuticalsmajorTechnology or Integration · 1 June 2026Agios licensed exclusive global rights to Oscotec's cevidoplenib (next-generation SYK inhibitor) for immune thrombocytopenia. Oscotec received $25 million upfront with potential additional payments of up to $140 million in development and regulatory milestones plus tiered royalties on future net sales. Agios plans Phase 3 trials for ITP in H1 2028, targeting peak U.S. sales potential of up to $1 billion.
  • Yatiri BiomoderateStrategic or Co-development Partner · 24 March 2026Yatiri Bio entered exclusive option to in-license denfivontinib (FLT3/AXL dual inhibitor) for acute myeloid leukemia (AML). This provides Yatiri access to Oscotec's oncology asset.
  • SanofimajorTechnology or Integration · 15 December 2025Sanofi licensed global rights to ADEL-Y01 (anti-Tau antibody for Alzheimer's disease) co-developed with Oscotec since 2020. Deal valued at up to $1.04 billion including $80M upfront and additional milestone payments plus royalties. The antibody targets acetylated K280 (acK280) epitope and holds first-in-class potential.
  • Biorevert Inc.minorStrategic or Co-development Partner · 1 January 2023Co-development agreement for BRVT121 and BRVT221. Biorevert partnership expands Oscotec's pipeline in additional therapeutic areas.
  • Kanaph TherapeuticsmoderateStrategic or Co-development Partner · 1 March 2022Co-development agreement for EP2/4 program (OCT-598). Kanaph brings genome-driven drug target discovery capabilities; partnership worth approximately KRW 774.8 billion in cumulative deal value.
  • Beactica Therapeutics ABminorStrategic or Co-development Partner · 1 March 2021Joint R&D agreement for LSD1 program. Beactica contributes specialized drug discovery capabilities.
  • ADEL Inc.majorStrategic or Co-development Partner · 1 October 2020Co-development agreement for ADEL-Y01 (anti-Tau antibody for Alzheimer's disease). Oscotec contributed discovery expertise; ADEL advanced the program through Phase 1 before out-licensing to Sanofi in December 2025.
  • Ectodor Therapeutics Inc.internalOthers · 1 October 2020Oscotec established Ectodor Therapeutics Inc. as a subsidiary in October 2020 to support broader corporate strategy.
  • Janssen Pharma (Johnson & Johnson)majorTechnology or Integration · 1 November 2018Janssen licensed Lazertinib from Yuhan (which licensed from Oscotec subsidiary Genosco). Deal valued at $1.255 billion. Lazertinib is a 3rd generation EGFR inhibitor. FDA approved combination with Rybrevant in August 2024.
  • Yuhan CorporationmajorTechnology or Integration · 1 July 2015Oscotec licensed EGFR-targeted anti-cancer drug candidate (Lazertinib) to Yuhan in 2015. Yuhan further licensed to Janssen in 2018 for $1.255 billion. Yuhan distributes royalties to Oscotec (10-15% of net sales, distributed 6:2:2 with Genosco).

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Oscotec competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Oscotec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oscotec leadership team

Management profile

Number of profiles

Profiles6 records

Oscotec funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oscotec M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oscotec

What does Oscotec do?

Oscotec is a clinical-stage drug discovery company that discovers and develops small-molecule targeted therapeutics and biologics with novel mechanisms of action in oncology and immunology. The company monetizes its pipeline through out-licensing deals with global pharmaceutical partners, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Is Oscotec a public or private company?

Oscotec is a public company. It is classified as public and is currently operating.

When was Oscotec founded?

Oscotec was founded in 1999. It employs 11 to 50 people.

Where is Oscotec based?

Oscotec is headquartered in Seongnam, South Korea, in the Asia region.

How does Oscotec make money?

Two revenue lines are on record. Licensing Royalties are the primary driver. The others are milestone Payments.

Does Oscotec have an API?

No public API is recorded for Oscotec.

What industry is Oscotec in?

Oscotec's product category is Clinical-stage drug discovery and development. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingOSCOTEC Faces Court Petition for Appointment of InspectorOSCOTEC faces a Nov. 11, 2026, application to appoint an inspector in a corporate control dispute at Suwon District Court's Seongnam branch. The court sought directors' and auditors' views, including compensation arrangements if an independent lawyer is appointed inspector. OSCOTEC confirmed receipt on Nov. 16, 2026, and plans to respond through legal procedures.The future of tradingOSCOTEC Announces Extraordinary Shareholders MeetingOSCOTEC will hold an extraordinary shareholders' meeting on December 1, 2026, at the Korea Bio Park auditorium in Seongnam, South Korea. Shareholders will consider removing charter provisions requiring 80% support for certain director appointments and dismissals, and expanding eligibility for board chair to all directors. The agenda also includes electing three directors and appointing one non-standing auditor.The future of tradingOSCOTEC Reschedules Extraordinary Shareholder Meeting to Dec. 1 From Nov. 30OSCOTEC rescheduled its extraordinary shareholder meeting from Nov. 30 to Dec. 1, 2026. The revised agenda includes electing three directors via cumulative voting, one auditor, and amending the articles of incorporation to change board chair eligibility requirements.The future of tradingOscotec faces court bid to call extraordinary shareholder meeting amid control fightA court petition filed on Sep. 22, 2026, seeks permission for Oscotec to hold an extraordinary shareholders' meeting to vote on bylaw deletions and appoint three directors. The company confirmed receipt on Sep. 23, 2026, and plans to respond through legal procedures.NateOscotec, management rights dispute intensifies... Proposal for 3 new directors: Nate NewsShareholders of Oscotec applied to the Suwon District Court to convene an extraordinary general meeting, requesting deletion of two articles of incorporation and appointment of three new directors. The applicants proposed Mr. Go as inside director, Mr. Kim as other non-executive director, and Mr. Park as independent director. Oscotec said it will respond according to legal procedures.ZacksAGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over YearAgios Pharmaceuticals reported Q2 2026 earnings that beat estimates with a loss of $1.69 per share, narrower than the $1.86 consensus estimate, and revenues of $44.7 million surged 259.3% year over year driven by strong Pyrukynd sales and robust demand for Aqvesme following its U.S. commercial launch in January 2026. The company received EU approval for Pyrukynd in thalassemia in May and has an FDA decision on mitapivat for sickle cell disease due November 1, 2026, though shares fell 6.4% despite the earnings beat due to investor concerns over discontinuation of the tebapivat development program. Agios also entered a licensing agreement with Oscotec to acquire global rights to cevidoplenib, a next-generation spleen tyrosine kinase inhibitor for immune thrombocytopenia, with up to $1 billion peak sales potential.Stock TitanAgios Q2 Earnings: Mitapivat Net Revenue $44.7MAgios Pharmaceuticals reported second quarter 2026 financial results with mitapivat (PYRUKYND and AQVESME) generating $44.7 million in worldwide net revenues, a 259% increase from $12.5 million in Q2 2025, driven by the strong U.S. commercial launch of AQVESME for thalassemia. The FDA granted Priority Review for the mitapivat sNDA in sickle cell disease with a PDUFA goal date of November 1, 2026, while the European Commission approved PYRUKYND for thalassemia across all EU member states. The company also diversified its pipeline by licensing cevidoplenib from Oscotec for immune thrombocytopenia and advancing AG-236 into Phase 2/3 development for polycythemia vera, while discontinuing tebapivat in lower-risk MDS and sickle cell disease due to insufficient clinical benefit.GlobeNewswireAgios Reports Second Quarter 2026 Financial Results and Provides Business UpdateAgios Pharmaceuticals reported strong second quarter 2026 financial results, with mitapivat (PYRUKYND and AQVESME) generating $44.7 million in worldwide net revenues, a 259% increase from $12.5 million in Q2 2025, driven by the U.S. commercial launch of AQVESME for thalassemia. The company received FDA Priority Review for mitapivat's sNDA in sickle cell disease with a November 1, 2026 PDUFA goal date, while also securing European marketing authorization for PYRUKYND in thalassemia across all EU member states. Agios further expanded its pipeline through licensing cevidoplenib from Oscotec and advancing AG-236 into Phase 2/3 for polycythemia vera, though it will not advance tebapivat in lower-risk MDS or sickle cell disease following Phase 2 trial results.BioSpaceAgios Reports Second Quarter 2026 Financial Results and Provides Business UpdateAgios reported Q2 2026 net revenue of $44.7 million, up from $12.5 million a year earlier, with a net loss of $100.7 million. The company highlighted the U.S. launch of AQVESME in thalassemia, FDA Priority Review for mitapivat in sickle cell disease, and pipeline advances including cevidoplenib licensing and AG-236 Phase 2/3 initiation.Investing.comWhy This Biotechnology Stock is a Top Pick at TD Cowen Right Now By Investing.comTD Cowen has named Agios Pharmaceuticals its top pick in the biotechnology sector, citing the FDA's acceptance and priority review of the company's supplemental New Drug Application for mitapivat in sickle cell disease, with a PDUFA date set for November 1, 2026. The priority review designation signals regulatory alignment on the approval path, contradicting skeptics who had anticipated a Complete Response Letter, particularly after competitor Novo Nordisk published positive Phase 2 data for etavopivat. Agios also licensed exclusive global rights to cevidoplenib from Oscotec for immune thrombocytopenia while discontinuing development of tebapivat, following which H.C. Wainwright raised its price target on the stock.